Follow to see short succinct summaries of the latest papers in IBD that were TL;DR (Too Long; Didn't Read)
Created by Dr. Laura Targownik (@laura_tee_mdgi)
Hello TL;DR-IBD Followers!
Here is my latest video breaking down the QUASAR Study evaluating the efficacy of the IL-23 Inhibitor Guselkumab (TREMFYA) in Ulcerative Colitis!
Do IL-23s have a place in UC?
Should we use them First Line?
Are there differences between the IL-23s?
Watch, see if you agree, and comment!
New Video Dropping Tomorrow
Follow along for my capsule summary of the QUASAR study assessing the IL-23 Inhibitor GUSELKUMAB for patients with moderate to severe UC
Iβd like to thank the over 200 IBD, physicians and patients who have followed Too Long Didnβt Read: IBD in its first 48 hours
Please feel free to comment with your ideas for improvements, comments about the studies, and suggestions for papers you would like to see reviewed in the future
And please, continue to share this content with your circles. we would love to see over 1000 followers by the end of this month!
Welcome to TL;DR IBD (or Too Long, Didn't Read IBD), where I post succinct capsule summaries of the latest papers in IBD in 4 minutes, or less
In the first episode, I summarize the EXIT trial, which sought to evaluate whether withdrawal of Anti-TNF therapy is a reasonable option for IBD patients in long-term clinical remission
Please follow this account and share with your colleagues if you enjoyed this content
Link to the article in the comments
Welcome to TL;DR IBD (or Too Long, Didn't Read IBD), where I post succinct capsule summaries of the latest papers in IBD in 4 minutes, or less
In the first episode, I summarize the EXIT trial, which sought to evaluate whether withdrawal of Anti-TNF therapy is a reasonable option for IBD patients in long-term clinical remission
Please follow this account and share with your colleagues if you enjoyed this content
Link to the article in the comments